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The receptor-binding affinity of recombinant-derived interleukin-lp containing unprocessed N-terminal 
methionine (MAPV-) was 10-fold lower than protein containing the authentic N-terminal sequence (APV-). 
Structural analysis of the methionylated and non-methionylated proteins by NMR spectroscopy detected 
no (or minor) conformational differences. The differences in binding affinity, therefore, suggest that the ad- 
ditional N-terminal methionine causes a small, direct or indirect, perturbation of the receptor-binding re-
gion. 
Interleukin-l; Interleukin-I receptor; NMR; Methionine aminopeptidase; N-terminal processing 
1. INTRODUCTION 
The purification and characterization of 
recombinant-derived interleukin-lz] (IL-ld) have 
been recently described [1,2]. The purified protein 
was found to be a mixture of 80%o correctly pro- 
cessed protein (N-terminus = Ala) and 20% of an 
N-terminal-methionylated form. The presence of 
N-terminal Met in a mature polypeptide is not un- 
common and may be due to the difficulty which 
the processing enzyme methionine aminopeptidase 
experiences in removing Met when it is followed by 
a residue with large radius of gyration [3]. For 
recombinant-derived proteins produced in E. coli 
the removal of Met may also be compromised by 
the very high levels of accumulated protein which 
may simply saturate the processing enzyme(s). For 
IL-1/Y this is almost certainly true, since the 
purified protein can be readily de-methionylated in 
vitro using purified methionine aminopeptidase 
[4]. Partial removal of Met has also been reported 
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for some other recombinant-derived proteins pro- 
duced in E. coli [5,6]. 
Here, we have used a competition binding assay 
[7,8] to compare the receptor-binding affinities of 
N-terminal-methionylated an non-methionylated 
wild-type IL-lfl and also that of a mutant in which 
His 30 has been replaced by an Arg residue [7]. 
Surprisingly, in both instances, the methionylated 
proteins howed 10-fold lower receptor-binding af- 
finities compared to the corresponding non- 
methionylated forms. 
2. MATERIALS AND METHODS 
2.1. Preparation o f  methionylated and non- 
methionylated 1L-1/~ proteins 
N-terminal-methionylated and non-methionyl- 
ated IL-1/5' wild-type proteins were separated by 
chromatofocusing as described [2]. The mutant 
IL-1/Y His 30 , Arg was fractionated in a similar 
manner except that the sample, dialysed against 
20 mM Tris-HCl (pH 8.0) was applied to a fast 
liquid chromatography (FPLC) MonoP column 
equilibrated with 25 mM Bis-Tris-acetate (pH 7.3). 
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Polybuffers were removed by hydrophobic hro- 
matography using a phenyl-Superose HR 5/5 
(Pharmacia) column. Protein concentrations were 
Al~O determined by ultraviolet absorbance: an lcm = 
0.63 at 280 nm was used [1]. 
2.2. Preparation of methionine aminopeptidase 
and in vitro digestion f 1L-1/Y 
Methionine aminopeptidase was purified from 
Salmonella typhimurium and used for the in vitro 
processing of N-terminal-methionylated IL-1/? as 
in [4]. 
2.3. NMR spectroscopy 
Sample preparation and measurements were 
made as detailed elsewhere [7,8]. 
2.4. Analytical measurements 
Isoelectric focusing on thin-layer polyacryl- 
amide gels and SDS-polyacrylamide gel electro- 
phoresis (SDS-PAGE) were performed according 
to [1,2]. 
ment of the non-methionylated IL-IA? had no effect 
on binding affinity (fig.lA). 
Fig.2 shows a comparison of the 500 MHz ~H- 
NMR spectra from the methionylated form of 
IL-IAY and from the protein without the N-terminal 
Met. As can easily be appreciated both spectra re 
very similar, thus demonstrating that no gross con- 
formational differences exist between the two 
forms of IL-I~. The resonances arising from the 
additional Met are indicated at the top of the 
figure. The new methyl resonance is clearly visible 
in the one-dimensional spectrum, whereas the 
other resonances belonging to the additional Met 
were identified in a two-dimensional HOHAHA 
spectrum (not shown). A comparison of the two- 
dimensional spectra confirmed that only very small 
differences exist between the two protein forms. 
We could identify two shifts in a,-proton 
resonances and two in the methyl region; both are, 
however, extremely small (<0.05 ppm). Inciden- 
tally, one of the residues experiencing a shift is a 
2.5. 1L-1 receptor-binding assay 
The assay procedure has been described in detail 
elsewhere [7,81. 
3. RESULTS AND DISCUSSION 
As reported in [2], purified N-terminal- 
methionylated and non-methionylated wild-type 
IL-I~' exhibit single bands on SDS-PAGE (Mr -- 
17500) and the methionylated protein has an 
isoelectric point (pI = 6.55) approx. 0.25 pH units 
lower than the non-methionylated protein. Similar 
results were obtained with the corresponding IL-I~ 
mutant proteins (not shown). 
The methionylated wild-type IL-I~ had an ap- 
prox. 10-fold lower receptor-binding activity com- 
pared to the non-methionylated protein (fig.lA). 
To show that the reduced receptor binding was 
specifically due to the presence of N-terminal Met, 
N-terminal-methionylated IL-I~' was digested with 
an N-terminal-specific peptidase, methionine 
aminopeptidase, purified and utilized as described 
by Miller et al. [4]. As expected, removal of N- 
terminal Met resulted in a pI increase of 0.25 pH 
units with a concomitant 10-fold increase in 
receptor-binding affinity (fig.lA). Enzyme treat- 
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Fig.l. Competition binding assay of N-terminal- 
methionylated and non-methionylated IL-I~'. The 
indicated concentrations of unlabeled IL-I~' proteins 
were mixed at 4°C with 125I-IL-1cr (1 ng/ml) prior to 
addition of EL4-6.1 cells (5 x 105/tube). After 4 h at 
4°C, bound radioactivity was evaluated by centrifuga- 
tion of cells through an oil gradient. Data are expressed 
as percent inhibition of 125I-IL-I binding compared to 
untreated controls. (A) N-terminal non-methionylated 
IL-I~ treated (A) and non-treated (A) with methionine 
aminopeptidase are compared with N-terminal methio- 
nylated IL-1/Y treated (o) and non-treated (e) with 
protease. (B) N-terminal non-methionylated IL-1/5' with 
a His 30 ----, Arg substitution (m) and N-terminal- 
methionylated mutant IL-I/5' (n) are compared with the 
corresponding wild-type proteins. 
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Fig.2. 500 MHz ~H-NMR spectra of N-terminal-methionylated [Met( + )] and N-terminal non-methionylated [Met( - )] 
IL-I~' at 25°C. 
threonine (Thr b), whose spin system was iden- 
tified in an earlier study [8]. 
In a previous report it was shown that the IL - I~ 
mutant His 30 , Arg has a 100-fold lower 
receptor-binding affinty compared to wild-type 
protein [7]. Furthermore, analysis by NMR spec- 
troscopy indicated that this activity difference was 
not due to gross conformational changes [7]. The 
mutant protein used in the aforementioned study, 
similar to wild-type IL-ll3, consisted of approx. 
20% N-terminal-methionylated and 80% non- 
methionylated protein. It was, therefore, of  in- 
terest to see whether the presence of N-terminal 
Met also affected receptor binding of this protein. 
The result obtained, which indicated a 10-fold 
reduction in receptor-binding affinity (fig. 1B), was 
similar to that obtained with the corresponding 
wild-type proteins. The methionylated IL-1 mutant 
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has, therefore, almost a 1000-fold lower receptor- 
binding affinity compared to the wild-type non- 
methionylated protein. This simple additive 
decrease in binding affinity may indicate that the 
two protein modifications are producing indepen- 
dent, and probably indirect, perturbations of the 
receptor-binding region. If both N-terminal Ala 
and His 30 were directly involved in receptor 
binding, we might have expected larger, i.e. 
synergistic, rather than additive decreases in 
binding affinity as a result of modifying both 
residues. 
Obviously, in the absence of real structural in- 
formation on IL-1/? and its receptor, we can only 
speculate on the mechanism by which modification 
of the N-terminus of IL-I~' perturbs receptor 
binding. However, several recent reports are re- 
levant o this issue. Schrader et al. [10] have drawn 
attention to the N-terminal sequence homologies 
among several cytokines, including IL-I/? and 
interleukin-2 (IL-2). The N-terminal sequence of 
IL-1/~, namely Ala-Pro, is the most common se- 
quence, and the conservation of N-terminal Ala is 
suggested to have functional and/or structural 
significance. The results described herein would 
seem to support his prediction, at least for IL-lfl. 
In the case of IL-2, however, Yamada et al. [5] 
have reported that there is no difference in 
biological activity between N-terminal-methionyl- 
ated and non-methionylated protein. In this con- 
text, Wingfield et al. [1] also saw little difference 
in biological activity between methionylated and 
non-methionylated IL- 1/?. (Although the 
methionylated IL-I~ was consistently at least 
2-fold less active than the non-methionylated pro- 
tein, this was not considered significant in view of 
the inherent variability in the assay used.) In the 
case of IL-2, it would be of interest to compare the 
receptor-binding affinities of the methionylated 
and non-methionylated proteins. 
Various biologically active N-terminal deletion 
analogues of IL-1 have been reported [11,12], sug- 
gesting that the N-terminal region has no direct 
functional role. Since these reports were of a 
somewhat preliminary nature and since the 
chemical and physical properties of neither the 
control nor deletion analogues u ed were de- 
scribed, one must say that the structural and/or 




Recombinant-derived proteins produced in E. 
coli may contain N-terminal Met as a result of in- 
complete processing of initiating N-formylmethio- 
nine (see [13] for discussion). The presence of this 
additional residue on the N-terminus would be a 
concern if the protein in question were to be used 
in clinical studies [14,15]. Although there is no im- 
mediate clinical application envisaged for IL-lfl, 
the reduced receptor-binding affinity of the N- 
terminal-methionylated protein would make it 
seem worthwhile to use only the purified non- 
methionylated protein for detailed structural/ 
function studies. The methods and procedures 
outlined here and in the cited references provide 
routes to pure recombinant-derived IL-I~' with the 
chemical, and presumably the biological, proper- 
ties of the authentic protein. 
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